ADVA-OPTICAL-NETWORKING
25.6.2020 09:02:04 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Central Bank of Austria is deploying its FSP 3000 technology in a new, highly reliable, ultra-secure data center interconnect (DCI) network. With capacity for up to 32Gbit/s Fibre Channel and 100Gbit/s Ethernet services, the infrastructure provides robust, high-speed disaster recovery and business continuity capabilities that are essential for mission-critical operations. It’s protected by ADVA’s ConnectGuard™ Optical encryption and the real-time assurance of the ADVA ALM fiber monitoring solution. ADVA’s open modular FSP 3000 platform ensures that the bank’s redundant point-to-point system is easily scalable and highly efficient with space and power consumption. The network was installed by ADVA’s partners Componet and dacoso, who are also providing ongoing support with maintenance and SLA management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005079/en/
“Our customers demand world-class services with unbeatable security and availability. That’s why we’re committed to harnessing the most innovative technology on the market. Built on the ADVA FSP 3000 and secured by ConnectGuard™ Optical encryption, our new DCI network supports the fastest, most advanced SAN connectivity available, ensuring mission-critical data is always accessible and fully protected,” said Daniela Karanitsch, head of IT operations, Central Bank of Austria. “This flexible, high-capacity solution empowers us to tackle huge increases in data demand while also making significant savings on rack space and power consumption. What’s more, its efficiency and sustainability is further enhanced by ADVA’s ALM fiber monitoring technology, which provides round-the-clock visibility and assurance of the entire network.”
The Central Bank of Austria’s new network can transport up to 200Gbit/s on a single wavelength. It supports a wide range of services on one platform, including 1, 10, 25, 40 and 100Gbit/s Ethernet as well as 8, 16 and 32Gbit/s Fibre Channel. That flexibility enables the bank to maximize efficiency as it responds to changing customer requirements. Austria’s most sensitive financial data is now being safeguarded by encryption at the lowest network layer, guaranteeing resilient protection with none of the latency and performance problems that come with other security methods. ADVA’s FSP 3000 ConnectGuard™ Optical was the first encryption solution on the market to support Fibre Channel speeds up to 32Gbit/s. It’s still the only one capable of such speeds to achieve BSI-approved status, enabling its use for EU and NATO restricted data.
“Our FSP 3000 platform gives the Central Bank of Austria exceptionally fast, agile and robust disaster recovery and business continuity capabilities. And with our ALM technology, it delivers precise, real-time insight into the bank’s fiber plant so that any impairments or breaks can be rapidly repaired with minimal disruption. In fact, our ALM has already repaid the bank’s investment by identifying an issue at the service provider end and preventing outages from occurring,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “For a major national bank leasing dark fiber, secure connectivity is of paramount importance. With the low-latency, physical-layer encryption of our FSP 3000 ConnectGuard™, customers throughout Austria can now be sure of a frictionless experience and complete peace of mind when accessing their financial data.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005079/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
